C. Difficile

A phase 2 trial published in The Lancet Infectious Diseases found that the investigational antibiotic CRS3123 achieved high clinical cure rates comparable to vancomycin while significantly reducing recurrence and preserving the gut microbiome in patients with Clostridioides difficile infection.

Nicholas Van Hise, PharmD, discusses a real world study, ROAR, showing that fecal microbiota, live-jslm (RBL), maintains strong efficacy and safety in preventing recurrent Clostridioides difficile infection (rCDI) in routine US clinical practice.

A Nature Microbiology study shows that structure-guided bile acid design can lock Clostridioides difficile toxin B into an inactive conformation, protecting mice from disease without disrupting the gut microbiome.

A large meta-analysis indicates opioid exposure may disrupt immunity and gut microbiota, increasing CDI vulnerability and potentially worsening clinical outcomes.

This week, learn about the first death from a meat allergy caused by ticks, Gilead reports positive top-line data showing its investigational combination therapy, bictegravir/lenacapavir was efficacious and safe, a discussion around antibiotic alternatives for MRSA, and more.

The tool's developer, LIV Process, says it has created a water-based reagent that illuminates Clostridioides difficile on surfaces so teams can verify cleaning in real time.

IND clearance enables a randomized, double-blind study of IMM-529 with standard care, while a forthcoming USU Travelan field readout will guide dosing strategy.

The foundation has unveiled its 2025 campaign, highlighting the deadly toll and long-term consequences of these infections through nationwide events, education initiatives, and tributes throughout November.

This week review more highlights from IDWeek, and why one researcher is predicting a milder avian influenza season.

Ed J Kuijper, MD, PhD details who is at highest risk for rCDI, how to interpret NAAT–toxin results, and how to sequence fidaxomicin, vancomycin, and microbiota-based therapies.

This week, there are C diff and hepatitis roundup reports, how COVID-19 has disrupted traditional respiratory virus patterns with summer surges now preceding the typical winter influenza season, a review of a trial comparing dalbavancin with standard intravenous therapy for Staphylococcus aureus, and more.

Although the number of people with knowledge about the infection rose, the results demonstrate a continued need for further education and awareness among the public.

A recent publication describes the results of a clinician survey conducted in 2024 regarding preferences and actual practices in the management of C difficile infection in adults.

The financing supports phase 3 evaluation of Sidiprev, a first-in-class, nonantibiotic therapy designed to prevent C difficile infections, a leading US health care–associated threat.

This week, expert insights highlighted progress in reducing C difficile with electronic hand hygiene monitoring, advancing HIV prevention with lenacapavir, updating COVID-19 vaccines for high-risk groups, and more.

C difficile remains a major healthcare-associated infection. Despite clear guidelines, hand hygiene compliance often falls short, creating gaps between policy and practice. A case study from a hospital showed that after implementing an electronic hand hygiene monitoring system with behavior prompts, compliance improved.

Systematic review finds FMT and standardized microbiome products outperform antibiotics in efficacy and safety.

C difficile carriers faced a higher baseline risk for hospital-onset infection compared to noncarriers, and this risk was not significantly influenced by antibiotic use.

This week, predictive microbiome models for C difficile, synergistic antibiotic strategies for E faecalis, to pharmacy-led hepatitis C care, and more.

A new study finds that personalized gut microbiome models may predict C difficile colonization risk and guide targeted probiotic treatment.

The most successful FMT approach involved administering multiple-dose capsules or colonoscopy following an extended course of antibiotic pretreatment.

This week, a mother's struggle with C difficile during pregnancy, racial disparities in COVID-19 treatment, Supreme Court decision preserving access to HIV prevention, and more.

Sara Embry discusses her experience with the infection while pregnant and as a mother to young children as well as finding the Peggy Lillis Foundation to help her cope with the infection and subsequently work as a peer support volunteer for the organization.

The role of oral vancomycin in preventing recurrence of C difficile infection (CDI) in at-risk persons receiving systemic antibiotic for non-CDI infection remains unclear after randomized trial.

This week, Moderna’s mRNA-1010 flu vaccine showed strong phase 3 results, new research reveals that FMT may fail due to functional mismatches between donor microbes and the recipient’s gut, and more.